YOKNEAM, Israel, July 30 /PRNewswire-FirstCall/ -- Lumenis Ltd
(Nasdaq: LUME) announced today the appointment of two new Directors to the
Board, Dr. Shlomo Segev and Alexander Yuhjtman, who will serve as company
outside directors, and the resignation of Prof. Boleslaw Goldman as a
director.
Dr. Shlomo Segev has been a Medical Director of the Institute of Medical
Screening at the Sheba Medical Center located in the Tel Hashomer Hospital in
Tel Aviv, Israel since 1985. Additionally, he has been the Medical and
Research Director in Neopharm Pharmacological Company since 1981, and has been
an active member of the Israeli Medical Association since 1975.
Alexander Yuhjtman was until 2002 a consultant for Bank Hapoalim, B.M. on
international banking matters. He previously served as Deputy Chief Executive
Officer and a member of the board of management of Bank Hapoalim and served in
many executive roles in international assignments over his 32 year career at
Bank Hapoalim. He is currently a director of "Isal" Investments.
Prof. Boleslaw Goldman resigned from the Board effective immediately due
to extending his assignment by the Israeli Health Ministry as the Director of
the Chaim Sheba Medical Center, Tel-Hashomer, Israel, which precludes his
service in any additional office.
About Lumenis
Lumenis develops, manufactures, and markets state-of-the-art proprietary
laser and intense pulsed light devices. Its systems are used in a variety of
aesthetic, ophthalmic, surgical and dental applications, including skin
treatments, hair removal, non-invasive treatment of vascular lesions and
pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy,
benign prostatic hyperplasia, open angle glaucoma, diabetic retinopathy,
secondary cataracts, age-related macular degeneration, vision correction,
neurosurgery, dentistry and veterinary. For more information about the Company
and its products log on to http://www.lumenis.com .
The statements in this press release that are not historical facts are
forward-looking statements which are subject to risks and uncertainties. The
Company's actual results could differ materially from those anticipated in the
forward looking statements based on a variety of factors, including, among
others: uncertainties with respect to market acceptance of the Company's
products, obtaining regulatory approvals for new products or for the sale of
existing products in new markets and enforcement of intellectual property
rights; risks associated with competition and competitive pricing pressures,
economic conditions generally, the Company's international operations and the
Company's ability to integrate its operations with those of acquired
businesses; the outcome of the Securities and Exchange Commission
investigation and several securities class action lawsuits to which the
Company is subject; uncertainties relating to the Company's continuing
liquidity; and other risks detailed from time to time in the reports filed by
Lumenis with the SEC, including its annual report on Form 10-K and quarterly
reports on Form 10-Q.
Contact: Kevin Morano
CFO
212-515-4187
SOURCE Lumenis Ltd
 back to top
Related links:
http://www.lumenis.com
CONTACT:
Kevin Morano, CFO of Lumenis Ltd,
+1-212-515-4187
|
